# The Study of JMT101 Combined With Irinotecan as a ≥3rd-Line Treatment in Metastatic Colorectal Cancer

Source: https://onco.cc/trials/nct07134205/  
OnCo record `nct07134205` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of JMT101, fOLFIRI (5-FU, leucovorin, irinotecan) and regorafenib in colorectal cancer, run by Shanghai JMT-Bio Inc., not yet recruiting.

## Summary

The Study of JMT101 Combined With Irinotecan as a ≥3rd-Line Treatment in Metastatic Colorectal Cancer is a phase 3, randomised interventional study registered as NCT07134205 by Shanghai JMT-Bio Inc., with a registry enrolment figure of 252 participants, started 2025-10-01 and due to reach its primary completion in 2027-06-01. Interventions recorded: JMT101; Irinotecan; Regorafenib. Conditions listed: Metastatic Colorectal Cancer (mCRC). Primary outcome: Progression-free Survival (PFS). Colorectal eligibility wording from the registry: "Pathological diagnosis as metastatic colorectal adenocarcinoma, with RAS and BRAF wild-type and non-dMMR/MSI-H;". No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-09-24
- Tags: ctgov-ingest; colorectal-deep-dive
- Registry id: NCT07134205
- Phase: 3
- Setting: A Randomized, Open-label, Multicenter Phase III Clinical Study of JMT101 in Combination With Irinotecan in Third-line and Beyond Treatment of Metastatic Colorectal Cancer
- Sponsor: Shanghai JMT-Bio Inc.
- Enrolled: 252

## Sources

- ClinicalTrials.gov NCT07134205: https://clinicaltrials.gov/study/NCT07134205

## Connected records

- cancers: [Colon cancer (adenocarcinoma of the colon)](https://onco.cc/cancers/colon-cancer/), [Mismatch-repair deficient (MSI-high) colorectal cancer](https://onco.cc/cancers/msi-high-colorectal/), [Rectal cancer](https://onco.cc/cancers/rectal-cancer/)
- technologies: [Anti-angiogenic therapy](https://onco.cc/technologies/antiangiogenic/), [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/), [Small-molecule kinase inhibitors](https://onco.cc/technologies/kinase-inhibitors/), [Topoisomerase-I inhibitors (and ADC payloads)](https://onco.cc/technologies/topoisomerase-inhibitors/)
- drugs: [FOLFIRI (5-FU, leucovorin, irinotecan)](https://onco.cc/drugs/folfiri/), [JMT101](https://onco.cc/drugs/jmt101/), [Regorafenib](https://onco.cc/drugs/regorafenib/)
- terms: [Colorectal cancer trials open today (registry snapshot)](https://onco.cc/terms/colorectal-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct07134205.json